BridgeBio Oncology Therapeutics BBOT
NASDAQ BBOT
$3.89 -0.05 (-1.27%)
At close: Oct 2, 2026 · 4:00 PM EDT

BridgeBio Oncology Therapeutics (BBOT) Return on Equity [ROE] (2025 - 2026)

Updated

BridgeBio Oncology Therapeutics' Return on Equity [ROE] came in at -57.22% for Q2 2026, down 14.64 percentage points from the prior quarter.

Analysis

BridgeBio Oncology Therapeutics (BBOT) Return on Equity [ROE] (2025 - 2026) Analysis & Trends

For FY2025, BridgeBio Oncology Therapeutics' Return on Equity [ROE] was -125.46%.

  • The five-year range for quarterly Return on Equity [ROE] is -107.76% (Q3 2025) to -33.05% (Q4 2025).
  • Business Quant data shows BBOT's Return on Equity [ROE] at -42.58% (Q1 2026), -33.05% (Q4 2025) and -107.76% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 25.32%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn -
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 84.40%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 21.39%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 83.75%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -18.38%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 4.97%
10 BridgeBio Oncology Therapeutics 315.65 Mn -1.06 Bn - -57.22%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -57.22%
Mar 31, 2026 -42.58%
Dec 31, 2025 -33.05%
Sep 30, 2025 -107.76%
API Access

BridgeBio Oncology Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=BBOT&period=max&api_key=YOUR_API_KEY